Genitourinary Malignancy
Renal cell carcinoma: The emerging role of adjuvant and neoadjuvant therapy
Alastair W. S. Ritchie, MD
Medical Research Council
London, United Kingdom
Intermediate-risk renal cell carcinoma: Best choice and sequencing of therapy
Camillo Porta, MD
IRCCS San Matteo University Hospital
Pavia, Italy
PSA-only relapse following local therapy for high-risk prostate cancer
Kurt Miller, MD
Benjamin Franklin Medical Center
Berlin, Germany
Hormone-responsive prostate cancer with bone metastases: How should therapy be sequenced?
Peter Mulders, MD, PhD
University Medical Center Nijmegen
Nijmegen, The Netherlands
Castration-resistant prostate cancer: Optimal management of a patient with good performance status
Camillo Porta, MD
IRCCS San Matteo University Hospital
Pavia, Italy
Gynecologic Malignancy
Initial systemic therapy for ovarian cancer
Nicoletta Colombo, MD
University of Milan-Bicocc
European Institute of Oncology
Milan, Italy
Stage IIIB ovarian cancer: Recurrence >12 months following completion of induction chemotherapy
Eric Pujade-Lauraine, MD, PhD
Centre Hospitalier Universitaire
Hotel-Dieu, Paris, France
